



# Donor-Derived Cell-Free DNA in Pancreas-Kidney, Heart-Kidney, and Liver-Kidney Multiorgan Transplant Recipients (MOTR)

Gaurav Gupta<sup>1\*</sup>, David Wojciechowski<sup>2</sup>, Alp Sener<sup>3</sup>, Timothy Gong<sup>4</sup>, Ty B. Dunn<sup>5†</sup>, Nadiesda Costa<sup>6</sup>, Jon S. Odorico<sup>7</sup>, Reem Daloul<sup>8†</sup>, Vinayak S. Rohan<sup>9</sup>, D. Giovanni Biagini<sup>10</sup>, David Barnes<sup>10</sup>, Navchetan Kaur<sup>10</sup>, Geethanjali Gude<sup>10</sup>, Ebad Ahmed<sup>10</sup>, Jing Xie<sup>10</sup>, Catherine J. Spellacy<sup>10</sup>, Nour Al Haj Baddar<sup>10</sup>, Michelle S. Bloom<sup>10</sup>, Zachary Demko<sup>10</sup>, Adam Prewett<sup>10</sup>, Phil Gauthier<sup>10</sup>, Sangeeta Bhorade<sup>10</sup>, Hossein Tabriziani<sup>10</sup> and Sanjeev K. Akkina<sup>11</sup> on behalf of the MOTR study investigators

<sup>1</sup>Virginia Commonwealth University, Richmond, VA, United States, <sup>2</sup>UT Southwestern Medical Center, Dallas, TX, United States, <sup>3</sup>Western University, Schulich School of Medicine and Dentistry, London, ON, Canada, <sup>4</sup>Baylor University Medical Center, Dallas, TX, United States, <sup>5</sup>Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States, <sup>6</sup>MedStar Georgetown University Hospital, Washington, DC, United States, <sup>7</sup>Medical College of Wisconsin, Milwaukee, WI, United States, <sup>8</sup>The Ohio State University, Columbus, OH, United States, <sup>9</sup>Northwestern University Feinberg School of Medicine, Chicago, IL, United States, <sup>10</sup>Natera, Inc., Austin, TX, United States, <sup>11</sup>Loyola University Medical Center, Maywood, IL, United States

## OPEN ACCESS

### \*Correspondence

Gaurav Gupta,  
✉ gaurav.gupta@vcuhealth.org

### †Present address:

Ty B. Dunn,  
Medical College of Wisconsin,  
Milwaukee, WI, United States  
Reem Daloul,  
Allegheny General Hospital, Pittsburgh,  
PA, United States

**Received:** 30 October 2025

**Revised:** 18 December 2025

**Accepted:** 19 December 2025


**Published:** 19 January 2026

### Citation:

Gupta G, Wojciechowski D, Sener A, Gong T, Dunn TB, Costa N, Odorico JS, Daloul R, Rohan VS, Biagini DG, Barnes D, Kaur N, Gude G, Ahmed E, Xie J, Spellacy CJ, Al Haj Baddar N, Bloom MS, Demko Z, Prewett A, Gauthier P, Bhorade S, Tabriziani H and Akkina SK (2026) Donor-Derived Cell-Free DNA in Pancreas-Kidney, Heart-Kidney, and Liver-Kidney Multiorgan Transplant Recipients (MOTR). *Transpl. Int.* 38:15823. doi: 10.3389/ti.2025.15823

Donor-derived cell free DNA (dd-cfDNA) is an established biomarker for detection of rejection in single organ transplants; data is limited in multi-organ transplant (MOT) recipients. “Use of dd-cfDNA in Multi-Organ Transplant Recipients” (MOTR) was a multicenter, prospective, cross-sectional study that assessed dd-cfDNA fraction (%) and donor quantity score (DQS, cp/mL) in pancreas-kidney (PKT), heart-kidney (HKT), and liver-kidney (LKT) recipients. We explored dd-cfDNA baseline levels across the different organ combinations, and compared them to kidney-only (KT) and heart-only (HT) transplant recipients. Among 347 MOT recipients from 18 sites (PKT = 183, HKT = 57, LKT = 107), most (88.2%) had simultaneous transplants. Median dd-cfDNA levels in PKT and HKT recipients were not significantly different from KT; median dd-cfDNA levels among HKT recipients were significantly higher than in HT recipients ( $p < 0.001$ ). In LKT recipients, median dd-cfDNA was significantly higher compared to KT ( $p < 0.001$ ). dd-cfDNA showed associations with organ impairment indicated by abnormal values of pancreatic and liver enzymes in PKT and LKT. As the largest multi-center study to date evaluating dd-cfDNA levels in MOT recipients, MOTR showed that organ-specific physiology affects dd-cfDNA levels across organ transplant combinations, laying the foundation for future efforts to use dd-cfDNA to assess organ-specific signatures of allograft injury in MOT recipients.

**Keywords:** allograft rejection, dd-cfDNA, heart transplant, kidney transplant, multi-organ transplant



## INTRODUCTION

Multi-organ transplantation (MOT) is an increasingly important therapeutic strategy driven by the rising burden of chronic disease, aging patient population, and the complex interplay of multi-organ dysfunction. As more patients present with concurrent multiple organ failure, MOT is the optimal treatment, providing life-saving intervention [1, 2]. The number of patients undergoing MOT between 2011 and 2021 with a kidney and additional solid organ has grown 23.4% [3]. Clinical management of MOT recipients is significantly more complex than single organ transplant, requiring more resources for monitoring and coordination between multiple clinical teams. Thus, there is a growing need to understand the applicability of emerging non-invasive biomarkers in this expanding high-risk population.

The physiological rationale for MOT is well-established across different clinical scenarios. Simultaneous pancreas-kidney transplant (SPKT) improves outcomes in patients with diabetes and end-stage renal disease (ESRD) [4]. Heart-kidney transplantation (HKT) benefits patients with coexisting cardiac and renal failure, a common clinical scenario resulting from the inter-dependence of both organs [5], reducing the risk of calcineurin inhibitor (CNI)-induced nephrotoxicity during heart transplantation which has contributed to a six-fold rise in US transplants since 2010 [6]. Simultaneous liver-kidney transplantation (SLKT) treats end-stage liver disease with concomitant kidney impairment or ESRD [7, 8], a common complication in this population [9]. Also, patients who may not

qualify for a kidney transplant alone due to significant cardiac or hepatic dysfunction may qualify through the addition of the heart or liver allograft.

Traditional biomarkers for monitoring acute rejection (AR) in MOT are limited in their prognostic utility. For example, serum creatinine (sCr), proteinuria, amylase, lipase, and liver enzymes (like alanine aminotransferase (ALT), alkaline phosphatase (ALP), and aspartate aminotransferase (AST)) are non-specific and can be confounded by unrelated factors [10–12]. Heart transplant biomarkers like B-type natriuretic (BNP) and N-terminal pro-BNP (NT-proBNP) are weakly-associated with heart transplant rejection [13]. Although biopsy remains the gold standard, its invasive nature and susceptibility to sampling error highlight the need for non-invasive biomarkers with improved sensitivity and specificity for organ injury in patients with MOT.

Donor-derived cell-free DNA (dd-cfDNA) is a validated biomarker for detecting AR in kidney [14, 15], lung [16], and heart single-organ transplant recipients [17]. Numerous studies have consistently demonstrated the high negative predictive value and strong correlation of dd-cfDNA with molecular and histologic rejection phenotypes across single-organ transplant types [18–22]. While dd-cfDNA was historically reported as a fraction of total circulating cf-DNA, studies have demonstrated that quantification of the plasma concentration of dd-cfDNA improves discrimination of rejection and reduces confounding from fluctuations in total cfDNA [23, 24]. Moreover, the combination of dd-cfDNA fraction and a donor quantity score (DQS), which estimates the quantity of dd-cfDNA in copies per mL of patient's plasma, has also been shown to

**TABLE 1 |** Demographics and clinical characteristics of MOTR study patients.

Recipient characteristics	All patients (N = 347)	Pancreas-kidney Cohort (N = 183)	Heart-kidney cohort (N = 57)	Liver-kidney (N = 107)	P value <sup>a</sup>	Pairwise p-values <sup>b</sup> PKT-HKT PKT-LKT HKT-LKT
Age (years)	57.1 (48.7–65.9)	51.1 (45.4–57.3)	62.1 (54.6–68.9)	64.8 (59.3–71.1)	<0.0001	<0.0001 <0.0001 0.2901
Sex ratio					0.0398	0.1094
Male	224 (64.6%)	115 (62.8%)	45 (78.9%)	64 (59.8%)		1.0000
Female	123 (35.4%)	68 (37.2%)	12 (21.1%)	43 (40.2%)		0.0647
BMI (kg/m <sup>2</sup> )	28.2 (24.9–32.7)	27.2 (24.1–31.8)	28.9 (26.0–32.9)	29.0 (26.0–33.4)	0.0404	0.1958 0.0828 1.0000
Time from most recent transplant to dd-cfDNA testing (months)	23.5 (8.4–52.7)	33.8 (9.2–73.9)	13.1 (6.4–33.2)	19.0 (8.2–41.8)	0.0001	0.0003 0.0220 0.2001
Race					<0.0001	<0.0001 <0.0001 <0.0001
White	179 (51.6%)	82 (44.8%)	18 (31.6%)	79 (73.8%)		<0.0001
African American	96 (27.7%)	44 (24.0%)	32 (56.1%)	20 (18.7%)		<0.0001
Other	6 (1.7%)	4 (2.2%)	0 (0.0%)	2 (1.9%)		<0.0001
Asian	11 (3.2%)	3 (1.6%)	5 (8.8%)	3 (2.8%)		<0.0001
Unknown	55 (15.9%)	50 (27.3%)	2 (3.5%)	3 (2.8%)		<0.0001
Ethnicity					<0.0001	0.0002 <0.0001 1.000
Not hispanic or latino	263 (75.8%)	116 (63.4%)	53 (93.0%)	94 (87.9%)		<0.0001
Hispanic or latino	28 (8.1%)	16 (8.7%)	3 (5.3%)	9 (8.4%)		1.000
Unknown	56 (16.1%)	51 (27.9%)	1 (1.8%)	4 (3.7%)		0.7925 1.0000 0.2379
Contemporaneous DSA status to dd-cfDNA testing					0.1115	0.7925 1.0000 0.2379
Yes	23	12	7	4		0.7925 1.0000 0.2379
No	324	171	50	103		0.7925 1.0000 0.2379
Transplant sequence					<0.0001	0.8934 <0.0001 0.00181
Non-simultaneous	36 (10.4%)	7 (3.8%)	3 (5.3%)	26 (24.3%)		<0.0001
Simultaneous	303 (87.3%)	169 (92.3%)	52 (91.2%)	80 (74.8%)		0.00181
Repeat	8 (2.3%)	7 (3.8%)	2 (3.5%)	1 (0.9%)		<0.0001
Biopsies					<0.0001	<0.0001 0.0008 <0.0001
For-cause	49 (14.1%)	34 (18.6%)	7 (12.3%)	8 (7.5%)		<0.0001
For-protocol	48 (13.8%)	6 (3.3%)	27 (47.4%)	15 (14.0%)		0.0008
Not reported	250 (72.0%)	143 (78.1%)	23 (40.4%)	84 (78.5%)		<0.0001
Mortality status					0.7509	1.0000 1.0000 1.0000
Alive	345 (99.4%)	182 (99.5%)	57 (100.0%)	106 (99.1%)		1.0000
Died	2 (0.6%)	1 (0.5%)	0 (0.0%)	1 (0.9%)		1.0000
Kidney donor characteristics						
Donor age (years)	32.0 (22.0–41.0)	27.0 (20.0–35.0)	33.0 (27.0–45.0)	40.0 (30.2–49.0)	<0.0001	0.0009 <0.0001 0.0768
Donor relationship to recipient					0.1030	1.0000 1.0000 0.6259
Not related	342 (98.6%)	178 (97.3%)	57 (100.0%)	107 (100.0%)		1.0000
Biologically related	5 (1.4%)	5 (2.7%)	0 (0.0%)	0 (0.0%)		0.6259
Donor type					0.1190	1.0000 0.7031 0.0805
Living	11 (3.2%)	7 (3.8%)	3 (5.3%)	1 (0.9%)		1.0000
DCD	43 (12.4%)	22 (12.0%)	2 (3.5%)	19 (17.8%)		0.7031
DBD	270 (77.8%)	144 (78.7%)	47 (82.5%)	79 (73.8%)		0.0805
Not reported	23 (6.6%)	10 (5.5%)	5 (8.7%)	8 (7.5%)		<0.0001
KDPI	23.0 (6.0–41.0)	11.0 (0.0–26.0)	28.0 (15.2–46.5)	39.0 (24.0–64.0)	<0.0001	<0.0001 <0.0001 0.0424
Pancreas/Heart/Liver donor characteristics (non-simultaneous)						
Donor age (years)	28.0 (20.5–39.5)	20.0 (17.5–24.5)	29.0 (24.8–32.5)	33.0 (25.5–45.0)	0.0090	0.6017 0.0088 1.0000

(Continued on following page)

**TABLE 1 |** (Continued) Demographics and clinical characteristics of MOTR study patients.

Recipient characteristics	All patients (N = 347)	Pancreas-kidney Cohort (N = 183)	Heart-kidney cohort (N = 57)	Liver-kidney (N = 107)	P value <sup>a</sup>	Pairwise p-values <sup>b</sup> PKT-HKT PKT-LKT HKT-LKT
Donor type					0.0132	
DCD	3 (6.5%)	1 (7.1%)	0 (0.0%)	2 (7.4%)		
DBD	36 (78.3%)	7 (50.0%)	5 (100.0%)	24 (88.9%)		
Not reported	7 (15.2%)	6 (42.9%)	0 (0.0%)	1 (3.7%)		

Categorical variables are shown as median (IQR). BMI: body mass index, dd-cfDNA: Donor-derived cell-free DNA, DSA: donor specific antibodies, CPRA: calculated panel reactive antibody, DCD: donation after cardiac death, DBD: donation after brain death, KDPI: kidney donor profile index, CMV: cytomegalovirus, EBV: Epstein-Barr virus, HIV: Human immunodeficiency virus.

<sup>a</sup>Kruskal-Wallis test comparing PKT, HKT, and LKT, cohorts.

<sup>b</sup>Post-hoc Mann-Whitney U or Chi-Square test comparing PKT-HKT, PKT-LKT, and HKT-LKT, with Bonferroni correction for significant Kruskal-Wallis values.

improve accuracy in the detection of AR with rejection thresholds of  $\geq 1.0\%$  and/or  $\geq 78$  cp/mL in kidney [25, 26], and  $\geq 0.26\%$  and/or  $\geq 18$  cp/mL in heart transplants [27]. While dd-cfDNA has been studied and characterized in SPKT recipients in a single-center study [28], its behavior in other MOT combinations remains largely unexplored, highlighting the need for additional research.

Here we introduce the “Use of dd-cfDNA in Multi-Organ Transplant Recipients” (MOTR) study; a multicenter, prospective, cross-sectional study designed to evaluate the dd-cfDNA baseline levels in real-world cohort of MOT recipients who were either clinically stable or who underwent a scheduled biopsy of at least one transplanted organ. This study analyzed dd-cfDNA levels, as a fraction (%), and donor quantity score (DQS; copies/mL) in pancreas-kidney (PK), heart-kidney (HK), and liver-kidney (LK) transplant recipients, and compared them to matched, real-world single-organ KT and HT recipients.

## MATERIALS AND METHODS

### Study Design

The MOTR study was an international, prospective, cross-sectional, multicenter study that evaluated dd-cfDNA baseline levels in patients with MOT. The studies involving human participants were reviewed and approved by local or central institutional review boards (IRBs, **Supplementary Table S1**). All PK, HK and LK transplant recipients who met the eligibility criteria were consented according to the IRB-approved protocol. The study has been performed in full adherence to the Declaration of Helsinki.

Patients were considered eligible for enrollment into the study if they met the following inclusion criteria: (1) age  $\geq 18$  years at the time of signing informed consent, (2) history of pancreas-kidney, kidney-heart, or liver-kidney transplant, (3) either considered clinically stable (defined as no history of rejection or no clinical indication of rejection within 3 months prior to enrollment in the study), or scheduled to undergo a biopsy of at least one of the transplanted organs, (4) able to read, understand, and provide written informed consent, and (5) willing and able to comply with the study-related procedures. Patients were excluded from this study if, at the time of enrollment they (1) were pregnant, (2) were on dialysis, (3) had received an allograft from an identical twin, and/or (4)

had more than 2 unique organ transplant types (i.e.: pancreas, liver, heart).

Clinical and biological data related to recipient characteristics, donor characteristics, transplant procedure, and contemporaneous laboratory tests including SCr, lipase, amylase, ALP, AST, ALT, DSA, and viral loads, were collected for patients in both the stable arm and the biopsy-matched arm (**Table 1**).

### dd-cfDNA Testing

dd-cfDNA samples were analyzed using the methodology previously described (the Prospera™ test; Natera, Inc., Austin, TX) [29]. Blood samples for dd-cfDNA testing were collected in two 10 mL Streck Cell-Free DNA BCT tubes and shipped at room temperature to Natera’s Clinical Laboratory Improvement Amendments-certified and College of American Pathologists-accredited laboratory. Samples were processed within 8 days of collection, or according to previously validated standard operating protocol [30]. The algorithm was designed to provide a single composite value by combining non-recipient cfDNA for both dd-cfDNA % and DQS, which is an estimate of the concentration of dd-cfDNA in plasma reported as genomic copies per mL (cp/mL). Blood draws for dd-cfDNA testing were performed within 0–7 days before biopsy in the biopsy-matched arm, or according to clinical standard in the stable arm. Results of the investigational test (dd-cfDNA) were not shared with the patients or the attending physicians, and thus not used in patient management.

### Biopsy Classification

Allograft biopsies of kidney, pancreas, heart, and liver transplants were graded as previously reported [31–34]. Biopsy reports were centrally reviewed by pathologists for data accuracy.

### Statistical Analysis

dd-cfDNA levels in PKT, HKT, LKT recipients were compared to real-world cohorts of KT and HT recipients matched for time post-transplant.

Statistical analyses were performed in Python (3.8.10). Normally distributed variables were reported as mean and standard deviation; non-normally distributed variables were reported as median and interquartile range (IQR). Categorical variables were represented as counts and percentages and evaluated using Chi-square test as appropriate. Kruskal-Wallis

tests were performed for groupwise comparisons. For significant p-values, post-hoc tests of chi-square or Mann Whitney U tests were performed, as appropriate, with Bonferroni corrections for multiple testing.

Random forest classifiers were applied to identify the relationship between known clinical variables and positivity of dd-cfDNA (i.e., high risk by dd-cfDNA) testing. dd-cfDNA positivity was defined using the clinical thresholds established for kidney-alone transplant rejection (dd-cfDNA% $\geq$ 1.0% OR DQS $\geq$ 78.0 cp/mL) for the PKT and HKT cohorts, and an investigational, unvalidated threshold for liver-alone transplant rejection (dd-cfDNA% $\geq$ 10.0%) based on prior studies [35–37] for the LKT cohort. Modeling was not feasible in the HKT cohort due to the limited number of dd-cfDNA-positive cases. Modeling included PKT cases with complete known matched eGFR (estimated glomerular filtration rate), amylase and lipase values, and LKT cases with complete known matched eGFR, ALP, AST, and ALT values, and was trained on these values along with time from transplant, Kidney Donor Profile Index (KDPI), and body mass index (BMI) and optimized for F1 score. The Shapley values of these features were assessed on a holdout random set of 20% of the complete cases.

Spearman correlation analyses were performed between dd-cfDNA (% cp/mL) and the clinical biomarkers relevant to each transplanted organ, as described above. For each variable pair, correlation was calculated using cases with complete data.

## SRTR Database

This study used data from the Scientific Registry of Transplant Recipients (SRTR). The SRTR data system includes data on all donor, wait-listed candidates, and transplant recipients in the US, submitted by the members of the Organ Procurement and Transplantation Network (OPTN). The Health Resources and Services Administration (HRSA), U.S. Department of Health and Human Services provides oversight to the activities of the OPTN and SRTR contractors. Contemporaneous data from the Scientific Registry of Transplant Recipients (SRTR) was assessed for comparison.

The data reported here have been supplied by the Hennepin Healthcare Research Institute (HHRI) as the contractor for SRTR. The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy of or interpretation by the SRTR or the U.S. Government.

Contemporaneous data from SRTR were queried to compare the MOTR study cohorts (PKT, HKT, and LKT) to the corresponding national cohorts for each MOT type, to assess representativeness and generalizability. Variables included MOT recipient age, sex, BMI, race/Ethnicity, and repeat transplant status as indicated in **Supplementary Table S2**.

## RESULTS

### Study Cohort

Between October 2020 and June 2022, 385 subjects from 18 sites were enrolled in the MOTR Study (**Supplementary**

**Table S1**). Of these, 38 subjects were excluded due to ineligibility or lack of valid dd-cfDNA testing (e.g., insufficient plasma volume). Of the remaining 347 transplant recipients, 183 had PKT, including 169 with a simultaneous pancreas-kidney transplant (SPKT; 92.4%), 7 with a pancreas-after-kidney transplant (PAKT; 3.8%). 7 patients (3.8%) underwent repeat transplant following a kidney-pancreas transplant: Four received kidney retransplant after SPK, and three received a pancreas retransplant (one after PAK, two after SPK). 57 subjects had HKT, including 54 with a simultaneous heart-kidney transplant (SHKT; 94.7%) and 3 with a kidney-after-heart transplant (KAHT; 5.3%). 107 subjects had LKT including 80 with a simultaneous kidney-liver transplant (SLKT; 74.8%), 24 with a kidney-after-liver transplant (KALT; 22.4%), two with a liver-after-kidney transplant (LAKT; 1.9%), and one (0.9%) with a liver re-transplant following a kidney-after-liver transplant (**Figures 1, 2**).


The MOTR cohort was 64.6% male (n = 224), had a median age of 57.1 y (IQR: 48.7–65.9), and a median BMI of 28.2 kg/m<sup>2</sup> (IQR: 24.9–32.7). Patients were 51.6% White, 27.7% African American, and 8.1% Hispanic and/or Latino. In the PKT, HKT, and LKT cohorts, 3.8% (7/183), 5.3% (3/57), and 0.9% (1/107) of the transplanted kidneys were donated by living donors, respectively. The median KDPI across all deceased donor's kidney transplants was 23.0 (IQR: 6.0–41.0). The majority (72%) of MOTR participants were considered clinically stable at enrollment, and the remaining 28% underwent biopsy; (*for-cause*: n = 49, 50.5%; *for-protocol*: n = 48, 49.5%) (**Table 1**). *For-cause* and *for-protocol* biopsies were observed in 18.6% and 3.3% of PKT, 12.3% and 47.4% of HKT, and 7.5% and 14.0% of LKT recipients, respectively; 70% of all biopsies were performed on the transplanted kidney.

The covariates of the PKT, HKT, and LKT subcohorts, such as MOT recipient demographics including age, sex, and ethnicity, were also compared to a contemporaneous national cohort's covariates as represented in data requested from the SRTR (<https://www.srtr.org/>) (**Supplementary Table S2**).

### dd-cfDNA Fraction and DQS Estimates

In this analysis, a single dd-cfDNA test from each patient was used, along with a matched biopsy, when available. The median time from most recent transplant to dd-cfDNA testing was 23.5 months (IQR: 8.4–52.7) and was significantly longer in the PKT cohort (33.8 months) compared to the HKT (13.1 months) and LKT (19.0 months) cohorts (p < 0.05).

Among the PKT recipients, there were no significant differences in the median (IQR) dd-cfDNA % or DQS between the SPKT (dd-cfDNA%: 0.23% (0.13–0.47); DQS: 9 (4–17) cp/mL), PAKT (dd-cfDNA%: 0.13% (0.11–0.23); DQS: 4 (3–7) cp/mL) or those who underwent kidney or pancreas retransplant after PKT (dd-cfDNA%: 0.29% (0.21–0.44); DQS: 16 (6–22) cp/mL) cohorts and the KT cohort (dd-cfDNA%: 0.23% (0.12–0.48); DQS: 9 (5–20) cp/mL) (p = 0.38, 0.31, and 0.55, respectively) (**Figure 3A**). The distribution of total cfDNA paralleled that of both dd-cfDNA (%) and DQS (cp/mL) among these groups (**Supplementary Figure S1A**).




Similarly, among the HKT recipients, there were no significant differences in the median (IQR) dd-cfDNA % or DQS (cp/mL) between the SHKT (dd-cfDNA%: 0.21% (0.12–0.42); DQS: 10 (7–18) cp/mL) or the KAHT cohorts (dd-cfDNA%: 0.32% (0.30–0.39); DQS: 22 (15–23) cp/mL) and the KT cohort (dd-cfDNA%: 0.24% (0.12–0.51); DQS: 10 (5–22) cp/mL ( $p = 0.36, 0.47$ , respectively) (**Figure 3B**). Both the median dd-cfDNA % and DQS (cp/mL) were significantly higher among the SHKT cohort when compared to the HT cohort (dd-cfDNA%: 0.21% (0.12–0.42); DQS: 10 (7–18) cp/mL) vs. (dd-cfDNA%: 0.06 (0.02–0.21), DQS: 2 (1–11) cp/mL,  $p < 0.001$ ) (**Figure 3B**). There were no differences in total cfDNA when comparing SHKT and KAHT to KT and SHKT and KAHT to HT cohorts (**Supplementary Figure S1B**).

Among the LKT recipients, both the median (IQR) dd-cfDNA % and DQS for the SLKT (dd-cfDNA%: 3.92% (1.92–6.99); DQS: 147 (75–258) cp/mL) and KALT cohorts (dd-cfDNA%: 3.35% (1.59–5.14); DQS: 35 (73–284) cp/mL) were significantly higher than the KT (dd-cfDNA%: 0.23% (0.12–0.49); DQS: 9 (5–22) cp/mL;  $p < 0.001$  for both) (**Figure 3C**). Lower total cfDNA levels in the SLKT compared to the KALT cohort may contribute to

differences between dd-cfDNA% and DQS (cp/mL) observed between them (**Supplementary Figure S1C**).

## Patients With Biopsy-Proven Acute Rejection (BPAR)

While this study did not contain sufficient patients with BPAR to assess appropriate dd-cfDNA cutoffs for rejection risk in MOT, we felt it was still illustrative to interpret the data in the context of the validated kidney-only threshold, as we would expect the dd-cfDNA values for kidney-only transplant patients to approximate a lower-bound for the appropriate MOT rejection risk threshold. A total of three patients in the SPKT cohort had kidney BPAR, two of which had dd-cfDNA above the 1.0% threshold used to define increased rejection risk in KT recipients (**Supplementary Figure S2A**): one recipient with T-cell-mediated rejection (TCMR) had dd-cfDNA levels of 3.11% and 63 cp/mL, while two patients with chronic active antibody-mediated rejection (AMBR) had dd-cfDNA% of 0.51% and 1.59% and DQS of 21 and 55 cp/mL. Three patients among the LKT cohort had BPAR in the kidneys (**Supplementary Figure S2B**), including



TCMR 1A with dd-cfDNA of 1.32%, 86 cp/mL, chronic active ABMR (2.31%, 114 cp/mL), and ABMR (6.98%, 698 cp/mL). No patients in the HKT cohort showed acute rejection on biopsy (**Supplementary Figure S2B**). Of the remaining 91 biopsies, 68 showed no rejection, 18 showed other findings not representing rejection, and 5 consisted of limited sample tissue and were thus unable to be diagnosed.

### Patients With dd-cfDNA Values Above Thresholds for Kidney-Only Transplant Rejection


Of the 240 non-rejecting PKT and HKT recipients, 21 (19 PKT and 2 HKT) exceeded KT dd-cfDNA thresholds ( $\geq 1.0\%$  and/or  $\geq 78$  copies/mL). All but one of these transplants were simultaneous; the remaining one was a kidney re-transplant after SPK. Seven patients (33.%) underwent biopsies (6 kidney, 1 heart), all without significant findings. The remaining 14 patients (13 PKT, 1 HKT) were considered clinically stable and did not undergo biopsy; one of these had substantially

elevated amylase levels, while the other 13 were clinically stable by all parameters apart from dd-cfDNA. Of the 219 patients with dd-cfDNA below KT threshold, only one experienced BPAR (chronic-active ABMR).

Of the 107 subjects in the LKT cohort, 12 (11.2%; 11 SLKT, 1 KALT) had dd-cfDNA above 10%, which prior studies have posited as an appropriate threshold for rejection in liver-only transplants [35–37]. Two of these subjects received surveillance biopsies of the kidney, both demonstrating no rejection; no patients received biopsies of the liver.

### Variables Associated With Elevated dd-cfDNA Levels in MOT Recipients

We sought to identify the clinical variables in MOT recipients that were associated with elevated dd-cfDNA levels using a random forest classifier with the PKT (**Figure 4A**) and LKT (**Figure 4B**) cohorts. The traditional markers for respective organ function were chosen as variables. In the PKT cohort, the most influential variables included amylase, time since transplant, and



**FIGURE 3 |** Baseline dd-cfDNA fraction (%) and DQS (cp/mL) levels in the PKT **(A)**, HKT **(B)**, and LKT **(C)** sub-cohorts. Box-and-whisker plots display the median and interquartile range (IQR); whiskers extend to 1.5x IQR representing the expected data range; outliers beyond this range are shown as individual points. P values denote pairwise comparisons in dd-cfDNA levels between: **(A)** SPKT, PAKT, and PK-RT and KT cohorts, **(B)** SHKT, KAHT and KT, HT cohorts, **(C)** SLKT, KALT, LAKT, RT-LKT, (Continued)

**FIGURE 3** | KL-RT and KT cohorts. PKT: Kidney-Pancreas transplant, SPKT: Simultaneous Kidney-Pancreas transplant, PAKT: Pancreas-after-Kidney transplant, PK-RT: Pancreas-Kidney Repeat transplant, KT: Kidney transplant, HT: Heart transplant, HKT: Kidney-Heart transplant, KAHT: Kidney-after-Heart transplant, SLKT: Simultaneous kidney-liver transplant, KALT: Kidney-after-liver transplant, LAKT: Liver-after-kidney transplant, KL-RT: Kidney-liver Repeat transplant.

lipase. Shorter time post-transplant, higher amylase values, and higher lipase values were associated with higher likelihood of elevated dd-cfDNA (**Figure 4A**). Looking at the continuous relationship between dd-cfDNA and the laboratory markers in the PKT cohort, significant positive correlations were observed in the PKT cohort between dd-cfDNA% and amylase and lipase ( $p < 0.001$ ,  $0.006$ , respectively), as well as between DQS and amylase and lipase ( $p = 0.006$ ,  $0.027$ , respectively). eGFR did not show a significant association with dd-cfDNA in either the random forest model or using Spearman correlations (**Supplementary Figure S3**).

In the LKT cohort, the most influential variables in the random forest classifier were ALT, AST, and ALP. Higher liver enzyme profiles were associated with higher likelihood of elevated dd-cfDNA (**Figure 4B**). Across all dd-cfDNA levels in this cohort, significant positive correlations were observed between dd-cfDNA% and ALT and AST ( $p < 0.001$  for both), and between DQS and ALT and AST ( $p < 0.001$  for both). No significant correlations were found between dd-cfDNA levels and eGFR (**Supplementary Figure S4**).

As the model indicated a significant association between time post-transplant and the likelihood of elevated dd-cfDNA levels, we further assessed the relationship between dd-cfDNA and time post-transplant in the different MOT cohorts (**Supplementary Figure S5**). In the PKT and HKT cohorts, dd-cfDNA% and DQS (cp/mL) both decreased over time. Total cfDNA remained steady in the PKT cohort while the HKT cohort showed a dramatic decrease in the first 40 months post-transplant before stabilizing. Despite these fluctuations, dd-cfDNA levels in both cohorts remained below the validated thresholds for KT rejection. In the LKT cohort, dd-cfDNA % and DQS increased slightly over time, whereas the total cfDNA decreased slightly, before stabilizing.

## DISCUSSION


This study represents the largest comprehensive characterization of dd-cfDNA (fraction and quantity) baseline levels in MOT recipients, addressing a gap in transplant biomarker research in this growing high-risk population. With characteristics comparable to the national SRTR registry, this cohort reflects real-world diversity and provides reference data for these populations. Key findings show that dd-cfDNA baselines vary by MOT combination and were generally aligned with known dd-cfDNA patterns from the major contributing organ: PKT and HKT had values comparable to KT recipients, while the higher dd-cfDNA levels in LKT recipients likely reflected the larger dd-cfDNA contribution from the liver transplants. Further, our data show associations between elevated dd-cfDNA and abnormal levels of traditional biomarkers used to test allograft functions indicating that dd-cfDNA levels reflect functional impairment of the respective transplanted organ (kidney, liver). Collectively, these data may help establish dd-cfDNA baseline levels

for different MOT combinations, underscoring the potential for dd-cfDNA to serve as a non-invasive biomarker for rejection risk assessment in MOT recipients.

The release of dd-cfDNA from transplanted organs is influenced by several factors, including order of organ transplantation, organ size, organ vascularization, and cellular turnover rate [38]. The broad inclusion criteria include patients with both simultaneous and sequential transplants, allowing us to explore the impact of the order of organ transplant on dd-cfDNA levels. Our data suggests that the pancreas is the minor dd-cfDNA contributor in PKT recipients as the levels in SPKT were comparable to those of KT recipients. Similarly, the baseline dd-cfDNA levels in the HKT recipient's cohort, including SHKT and KAHT, were comparable to those of KT recipients and significantly higher in SHKT than those of HT recipients, suggesting heart is the minor dd-cfDNA contributor relative to kidney. In contrast, dd-cfDNA levels were higher among the LKT cohort compared to KT recipients which is consistent with previous reports that LT recipients exhibit significantly higher dd-cfDNA levels than other solid organ transplants [35–37]. Given these data, it is not surprising that in this cohort, 2/3 PKT patients with kidney BPAR had dd-cfDNA above the 1.0% threshold established for KT rejection, as were 3/3 of the LKT patients with BPAR in the kidney. Of note, none of the three LKT patients with BPAR in the kidney had dd-cfDNA% above the exploratory 10% threshold proposed for liver transplant (LT) rejection; likely due to the lack of evidence of rejection in the liver of these patients. Taken together, these data suggest that the dd-cfDNA levels from the organ with the higher baseline may obscure rejections in the organ with the lower dd-cfDNA baseline, as seen in LKT and HKT (**Supplementary Figure S2C**). These findings underscore the importance of considering organ-specific dd-cfDNA levels when interpreting combined dd-cfDNA results in MOT populations and how it can be extrapolated from those established in single organ transplant recipients.

The clinical value of dd-cfDNA in MOT is further supported by its associations with abnormal levels in traditional biomarkers. In the PKT cohort, dd-cfDNA positivity was associated with increased serum amylase and lipase levels, suggesting that pancreas-derived injury signals correlate with higher dd-cfDNA release associated with rejection. Similarly, in the LKT cohort, strong associations between dd-cfDNA positivity and elevated liver enzymes (ALT, AST) are consistent with prior data suggesting that elevated dd-cfDNA levels in LT patients are associated with impaired liver function. These findings suggest that elevations in dd-cfDNA may serve as a sensitive indicator of allograft dysfunction across different transplanted organ types in MOT recipients.

In our study, the incidence of AR in our cohort (6.2%) was lower than that reported in similar MOT studies (24%) [39, 40] and (43%) [28]. This may reflect the large proportion of clinically stable patients enrolled in the study, which could be due to the relatively long post-transplant timeframe observed in this cohort. An added effect could be the immunoprotective role



hypothesized in MOT recipients, which could explain the seemingly counterintuitive finding that rejection rates are lower in MOT than in single organ transplant. Previous studies have shown that patients with dual organ transplants involving the heart and/or liver, tend to exhibit greater graft stability compared to single transplants alone [41, 42]. While it was previously thought that only MOT patients with a liver allograft experienced this immunoprotective effect, data has now shown that other simultaneously-transplanted organs also have this immunologic benefit [8, 43, 44]. This effect was not observed in sequential transplants, indicating that shared

antigenicity in simultaneous MOT may be required for immunoprotection to manifest [44]. In this study, the majority of participants were simultaneous MOT, which could have contributed to the lower incidence of AR via this 'immunoprotective' MOT mechanism.

A key challenge in MOT is identifying the graft undergoing rejection while managing immunosuppression to avoid toxicity. This becomes more complex when the transplanted organs are from different donors. The ability to discern the rejecting graft in these cases could be augmented by distinguishing between donor-specific cfDNA signatures, an approach proven feasible

in a recent study of pregnant kidney recipients where fetal- and graft-derived cfDNA were successfully differentiated [45]. Analogous advances in noninvasive prenatal testing (NIPT), such as SNP-based assays that enable precise attribution of cfDNA to individual fetuses in twin pregnancies, demonstrate that identifying the tissue origin of circulating cfDNA is feasible [46]. While this approach would not allow for differentiation of organ-specific dd-cfDNA in simultaneous MOT where the two transplanted organs are from the same donor, other studies have revealed that the cfDNA methylation patterns can be used to identify the tissue-of-origin, independent of donor number or type [47].

This study has several limitations. First, biopsy data were not available for 72% of patients, with the designation of “non-rejecting” made based on clinical characteristics, and of those patients with a biopsy, very few patients had a biopsy from both organs. Second, the overall number of BPAR cases was insufficient to allow determination of a dd-cfDNA threshold for the clinical detection rejection in MOT recipients. Third, the study did not differentiate between dd-cfDNA contributions from multiple donors in MOT recipients, limiting the ability to precisely attribute dd-cfDNA elevations to a specific organ. Fourth, this analysis was cross-sectional in nature, limiting the assessment of the dynamic changes of dd-cfDNA over time.

In conclusion, this study is the largest of its kind, in which dd-cfDNA% and DQS baselines were characterized in pancreas-kidney, heart-kidney, and liver-kidney transplant recipients. This study provides foundational insights into how dd-cfDNA levels differ among and between different combinations of MOT, how dd-cfDNA levels relate to more traditional rejection biomarkers, and how these levels may be interpreted relative to each other. Future longitudinal studies focusing on MOT cohorts are needed to develop clinically valid assays to detect and define thresholds of organ-specific dd-cfDNA and improve rejections detection in these complex transplant scenarios.

## DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/**Supplementary Material**, further inquiries can be directed to the corresponding authors.

## ETHICS STATEMENT

This study involved human subjects. All patients who met the eligibility criteria were consented according to local or central institutional review-board approved protocol, in accordance with local legislation and institutional requirements. A list of all IRB is provided in **Supplementary Table S1**.

## AUTHOR CONTRIBUTIONS

GaG contributed to conceptualization, investigation, methodology, resources, and writing (original draft, review and editing); DW, AS,

TG, TD, NC, JO, RD, VR, and SA contributed to investigation, resources, and writing (original draft, review and editing); DGB contributed to data curation, formal analysis, investigation, methodology, project administration, software, visualization, and writing (original draft, review and editing); DaB. contributed to formal analysis, investigation, software, visualization, and writing (review and editing); NK contributed to conceptualization, data curation, methodology, project administration, supervision, and writing (original draft, review and editing); GeG contributed to data curation, formal analysis, investigation, and writing (review and editing); EA contributed to methodology, validation, and writing (review and editing); JX and CS contributed to data curation, validation, and writing (review and editing); NA and MB contributed to visualization and writing (original draft, review and editing); ZD contributed to conceptualization, visualization, and writing (original draft, review and editing); AP contributed to conceptualization, project administration, supervision, and writing (review and editing); PG contributed to conceptualization, methodology, project administration, supervision, and writing (review and editing); SB contributed to conceptualization, project administration, supervision, and writing (original draft, review and editing); and HT contributed to conceptualization, methodology, project administration, supervision, validation, and writing (original draft, review and editing). All authors contributed to the article and approved the submitted version.

## FUNDING

The author(s) declared that financial support was received for this work and/or its publication. The authors declare that this study received funding from Natera, Inc. The funder had the following involvement with the study: study design, analysis, interpretation of data, writing of this article, and publication.

## CONFLICT OF INTEREST

GaG reports institutional research support from Merck and Veloxis (through Virginia Commonwealth University); consulting or advisory roles with Appellis, CareDx, Eurofins-Viracor, Natera, Novartis, and Specialist Direct; and honoraria from CareDx. He serves as Chair of the Kidney Pancreas Community of Practice of the American Society of Transplantation. DW received grants and/or contracts and consulting fees from Natera. AS reports institutional research support from the Canadian Institutes of Health Research (CIHR). TG reports research support from a grant funded by the American Society of Transplantation. JO reports support from Veloxis, received royalties for content contributed to UpToDate, and reports grant support from Breakthrough T1D. RD serves on the Data and Safety Monitoring Board (DSMB) of an NIH-sponsored clinical trial. SA reports consulting or advisory roles with Natera and Transplant Genomics and has received honoraria from Verici and Natera. DGB, DaB, NK, GeG, EA, JX, CS, NA, MB, AP, PG, SB, and HT are employees of Natera, Inc., and receive salary and may own stock and/or stock options. ZD is a

named inventor on several patents and is an employee of Natera, Inc., and receives salary and may own stock and/or stock options.

The remaining author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## GENERATIVE AI STATEMENT

The author(s) declared that generative AI was not used in the creation of this manuscript.

## REFERENCES

- Lang FM, Topkara VK. Evolving Indications and Management Patterns in Heart - Kidney Transplantation. *Curr Opin Nephrol Hypertens* (2025) 34(1): 16–22. doi:10.1097/MNH.0000000000001042
- Westphal SG, Langewisch ED, Miles CD. Current State of Multiorgan Transplantation and Implications for Future Practice and Policy. *Adv Chronic Kidney Dis* (2021) 28(6):561–9. doi:10.1053/j.ackd.2021.09.012
- Lentine KL, Smith JM, Miller JM, Bradbrook K, Larkin L, Weiss S, et al. OPTN/SRTR 2021 Annual Data Report: Kidney. *Am J Transpl* (2023) 23(2 Suppl. 1): S21–S120. doi:10.1016/j.ajt.2023.02.004
- Nagendra L, Fernandez CJ, Pappachan JM. Simultaneous pancreas-kidney Transplantation for end-stage Renal Failure in Type 1 Diabetes Mellitus: Current Perspectives. *World J Transpl* (2023) 13(5):208–20. doi:10.5500/wjt.v13.i5.208
- Banerjee D, Ali MA, Wang AY, Jha V. Acute Kidney Injury in Acute Heart failure-when to Worry and when Not to Worry? *Nephrol Dial Transpl* (2024) 40(1):10–8. doi:10.1093/ndt/gfae146
- Jain R, Kittleson MM. Evolutions in Combined Heart-Kidney Transplant. *Curr Heart Fail Rep* (2024) 21(2):139–46. doi:10.1007/s11897-024-00646-0
- Ali H, Begum Ozturk N, Herdan NE, Luu H, Simsek C, Kazancioglu R, et al. Current Status of Simultaneous liver-kidney Transplantation. *Hepatol Forum* (2024) 5(4):207–10. doi:10.14744/hf.2023.2023.0071
- Zhang IW, Lurje I, Lurje G, Knosalla C, Schoenrath F, Tacke F, et al. Combined Organ Transplantation in Patients with Advanced Liver Disease. *Semin Liver Dis* (2024) 44(3):369–82. doi:10.1055/s-0044-1788674
- Bera C, Wong F. Management of Hepatorenal Syndrome in Liver Cirrhosis: A Recent Update. *Therap Adv Gastroenterol* (2022) 15:17562848221102679. doi:10.1177/17562848221102679
- Jahn N, Voelker MT, Laudi S, Stehr S, Schneeberger S, Brandacher G, et al. Correlation of Different Serum Biomarkers with Prediction of Early Pancreatic Graft Dysfunction Following Simultaneous Pancreas and Kidney Transplantation. *J Clin Med* (2022) 11(9):2563. doi:10.3390/jcm11092563
- Zhou H, Hewitt SM, Yuen PS, Star RA. Acute Kidney Injury Biomarkers - Needs, Present Status, and Future Promise. *Nephrol Self Assess Program* (2006) 5(2):63–71.
- Germani G, Rodriguez-Castro K, Russo FP, Senzolo M, Zanetto A, Ferrarese A, et al. Markers of Acute Rejection and Graft Acceptance in Liver Transplantation. *World J Gastroenterol* (2015) 21(4):1061–8. doi:10.3748/wjg.v21.i4.1061
- Zhu V, Perry LA, Plummer M, Segal R, Smith J, Liu Z. Diagnostic Accuracy of Brain Natriuretic Peptide and N-terminal-pro Brain Natriuretic Peptide to Detect Complications of Cardiac Transplantation in Adults: A Systematic Review and meta-analysis. *Transpl Rev (Orlando)* (2023) 37(3):100774. doi:10.1016/j.ttre.2023.100774
- Sigdel TK, Archila FA, Constantin T, Prins SA, Liberto J, Damm I, et al. Optimizing Detection of Kidney Transplant Injury by Assessment of Donor-Derived Cell-free DNA via Massively Multiplex PCR. *J Clin Med* (2018) 8(1): 19. doi:10.3390/jcm8010019
- Bloom RD, Bromberg JS, Poggio ED, Bunnapradist S, Langone AJ, Sood P, et al. Cell-Free DNA and Active Rejection in Kidney Allografts. *J Am Soc Nephrol* (2017) 28(7):2221–32. doi:10.1681/ASN.2016091034
- Rosenheck JP, Ross DJ, Botros M, Wong A, Sternberg J, Chen YA, et al. Clinical Validation of a Plasma donor-derived Cell-free DNA Assay to Detect Allograft Rejection and Injury in Lung Transplant. *Transpl Direct* (2022) 8(4):e1317. doi:10.1097/TXD.0000000000001317
- Kim PJ, Olymbios M, Siu A, Wever Pinzon O, Adler E, Liang N, et al. A Novel donor-derived Cell-free DNA Assay for the Detection of Acute Rejection in Heart Transplantation. *J Heart Lung Transpl* (2022) 41(7):919–27. doi:10.1016/j.healun.2022.04.002
- Oellerich M, Sherwood K, Keown P, Schütz E, Beck J, Stegbauer J, et al. Liquid Biopsies: Donor-Derived Cell-free DNA for the Detection of Kidney Allograft Injury. *Nat Rev Nephrol* (2021) 17(9):591–603. doi:10.1038/s41581-021-00428-0
- Oellerich M, Budde K, Osmanodja B, Bornemann-Kolatzki K, Beck J, Schütz E, et al. Donor-Derived Cell-free DNA as a Diagnostic Tool in Transplantation. *Front Genet* (2022) 13:1031894. doi:10.3389/fgene.2022.1031894
- Akifova A, Budde K, Amann K, Buettner-Herold M, Choi M, Oellerich M, et al. Donor-Derived Cell-free DNA Monitoring for Early Diagnosis of antibody-mediated Rejection After Kidney Transplantation: A Randomized Trial. *Nephrol Dial Transpl* (2025) 40(7):1384–95. doi:10.1093/ndt/gfae282
- Madill-Thomsen KS, Hidalgo LG, Demko ZP, Gauthier PM, Prewett A, Lowe D, et al. Defining Relationships Among Tests for Kidney Transplant Antibody-Mediated Rejection. *Kidney Int Rep* (2025) 10(9):3225–38. doi:10.1016/j.ekir.2025.06.017
- Madill-Thomsen KS, Hidalgo LG, Mackova M, Campbell P, Demko Z, Felius J, et al. Defining the Relationships Among Four Tests for Assessing antibody-mediated Rejection in Heart Transplants in a Prospective, Observational Study. *J Heart Lung Transpl* (2025). doi:10.1016/j.healun.2025.10.024
- Oellerich M, Shipkova M, Asendorf T, Watson PD, Schauerer V, Mettenmeyer N, et al. Absolute Quantification of donor-derived Cell-free DNA as a Marker of Rejection and Graft Injury in Kidney Transplantation: Results from a Prospective Observational Study. *Am J Transpl* (2019) 19(11):3087–99. doi:10.1111/ajt.15416
- Whitlam JB, Ling L, Skene A, Kanellis J, Ierino FL, Slater HR, et al. Diagnostic Application of Kidney allograft-derived Absolute Cell-free DNA Levels During Transplant Dysfunction. *Am J Transpl* (2019) 19(4):1037–49. doi:10.1111/ajt.15142
- Bunnapradist S, Homkraisas P, Ahmed E, Fehring G, Billings PR, Tabriziani H. Using Both the Fraction and Quantity of Donor-Derived Cell-free DNA to Detect Kidney Allograft Rejection. *J Am Soc Nephrol* (2021) 32(10):2439–41. doi:10.1681/ASN.2021050645
- Halloran PF, Reeve J, Madill-Thomsen KS, Kaur N, Ahmed E, Cantos C, et al. Combining donor-derived Cell-free DNA Fraction and Quantity to Detect Kidney Transplant Rejection Using Molecular Diagnoses and Histology as Confirmation. *Transplantation* (2022) 106(12):2435–42. doi:10.1097/TP.0000000000004212
- Kim PJ, Olympios M, Sideris K, Tseliou E, Tran TY, Carter S, et al. A two-threshold Algorithm Using donor-derived Cell-free DNA Fraction and Quantity to Detect Acute Rejection After Heart Transplantation. *Am J Transpl* (2025) 25(9):1895–905. doi:10.1016/j.ajt.2025.04.021

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontierspartnerships.org/articles/10.3389/ti.2025.15823/full#supplementary-material>

28. Ventura-Aguilar P, Ramirez-Bajo MJ, Rovira J, Bañón-Maneus E, Hierro N, Lazo M, et al. Donor-Derived Cell-free DNA Shows High Sensitivity for the Diagnosis of Pancreas Graft Rejection in Simultaneous Pancreas-kidney Transplantation. *Transplantation* (2022) 106(8):1690–7. doi:10.1097/TP.0000000000004088
29. Bromberg JS, Bunnapradist S, Samaniego-Picota M, Anand S, Stites E, Gauthier P, et al. Elevation of Donor-derived Cell-free DNA Before Biopsy-proven Rejection in Kidney Transplant. *Transplantation* (2024) 108(9):1994–2004. doi:10.1097/TP.0000000000005007
30. Altug Y, Liang N, Ram R, Ravi H, Ahmed E, Brevnov M, et al. Analytical Validation of a Single-nucleotide Polymorphism-based Donor-derived Cell-free DNA Assay for Detecting Rejection in Kidney Transplant Patients. *Transplantation* (2019) 103(12):2657–65. doi:10.1097/TP.0000000000002665
31. Loupy A, Haas M, Roufosse C, Naesens M, Adam B, Afrouzian M, et al. The Banff 2019 Kidney Meeting Report (I): Updates on and Clarification of Criteria for T cell- and antibody-mediated Rejection. *Am J Transpl* (2020) 20(9):2318–31. doi:10.1111/ajt.15898
32. Drachenberg CB, Buettner-Herold M, Aguiar PV, Horsfield C, Mikhailov AV, Papadimitriou JC, et al. Banff 2022 Pancreas Transplantation Multidisciplinary Report: Refinement of Guidelines for T cell-mediated Rejection, antibody-mediated Rejection and Islet Pathology. Assessment of Duodenal Cuff Biopsies and Noninvasive Diagnostic Methods. *Am J Transpl* (2024) 24(3):362–79. doi:10.1016/j.ajt.2023.10.011
33. Stewart S, Winters GL, Fishbein MC, Tazelaar HD, Kobashigawa J, Abrams J, et al. Revision of the 1990 Working Formulation for the Standardization of Nomenclature in the Diagnosis of Heart Rejection. *J Heart Lung Transpl* (2005) 24(11):1710–20. doi:10.1016/j.healun.2005.03.019
34. Demetris AJ, Bellamy C, Hubscher SG, O’Leary J, Randhawa PS, Feng S, et al. 2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. *Am J Transpl* (2016) 16(10):2816–35. doi:10.1111/ajt.13909
35. Goh SK, Do H, Testro A, Pavlovic J, Vago A, Lokan J, et al. The Measurement of Donor-Specific Cell-Free DNA Identifies Recipients with Biopsy-Proven Acute Rejection Requiring Treatment After Liver Transplantation. *Transpl Direct* (2019) 5(7):e462. doi:10.1097/TXD.0000000000000902
36. Levitsky J, Kandpal M, Guo K, Kleiboeker S, Sinha R, Abecassis M. Donor-Derived Cell-free DNA Levels Predict Graft Injury in Liver Transplant Recipients. *Am J Transpl* (2022) 22(2):532–40. doi:10.1111/ajt.16835
37. Schutz E, Fischer A, Beck J, Harden M, Koch M, Wuensch T, et al. Graft-Derived Cell-free DNA, a Noninvasive Early Rejection and Graft Damage Marker in Liver Transplantation: A Prospective, Observational, Multicenter Cohort study. *Plos Med* (2017) 14(4):e1002286. doi:10.1371/journal.pmed.1002286
38. Keung N, Sandberg F, Sidler D, Banz V, Berzigotti A, Ng CKY, et al. (2025). Integrated Targeted Deep Sequencing Reveals Unique Tissue-Of-Origin And Donor-Derived Cell-Free DNA Signatures in Organ Transplant Recipients. medRxiv. doi:10.1101/2025.04.29.25326125
39. Moeller CM, Oren D, Fernandez VA, Rubinstein G, Lotan D, Mehlman Y, et al. Clinical Utility of Donor-Derived Cell-Free DNA in Heart Transplant Recipients with Multi-Organ Transplants. *Clin Transpl* (2024) 38(10):e15479. doi:10.1111/ctr.15479
40. Zaky ZS, Clifford SA, Fleming JN. Diagnostic Performance of Gene Expression and dd-cfDNA in Multiorgan Transplant Recipients. *Transpl Direct* (2025) 11(3):e1772. doi:10.1097/TXD.0000000000001772
41. Carey SA, Tecson KM, Jamil AK, Felius J, Wolf-Doty TK, Hall SA. Gene Expression Profiling Scores in Dual Organ Transplant Patients are Similar to Those in heart-only Recipients. *Transpl Immunol* (2018) 49:28–32. doi:10.1016/j.trim.2018.03.003
42. Itagaki S, Toyoda N, Moss N, Mancini D, Egorova N, Mikami T, et al. Outcomes of Simultaneous Heart and Kidney Transplantation. *J Am Coll Cardiol* (2023) 81(8):729–40. doi:10.1016/j.jacc.2022.11.053
43. Benseler V, Tay SS, Bowen DG, Bertolino P. Role of the Hepatic Parenchyma in Liver Transplant Tolerance: A Paradigm Revisited. *Dig Dis* (2011) 29(4):391–401. doi:10.1159/000329802
44. Rana A, Robles S, Russo MJ, Halazun KJ, Woodland DC, Witkowski P, et al. The Combined Organ Effect: Protection Against Rejection? *Ann Surg* (2008) 248(5):871–9. doi:10.1097/SLA.0b013e31817fc2b8
45. Tang J, Ligumsky LK, Woodruff K, Jang C, Charland N, Al Haj Baddar N, et al. A Novel Method to Estimate Donor-Derived Cell-Free DNA in Pregnant Kidney Transplant Recipients: A Proof-of-Concept Study. *Transpl Proc* (2025) 57(5):706–12. doi:10.1016/j.transproceed.2025.03.025
46. Norwitz ER, McNeill G, Kalyan A, Rivers E, Ahmed E, Meng L, et al. Validation of a Single-Nucleotide Polymorphism-Based Non-Invasive Prenatal Test in Twin Gestations: Determination of Zygosity, Individual Fetal Sex, and Fetal Aneuploidy. *J Clin Med* (2019) 8(7):937. doi:10.3390/jcm8070937
47. Sun K, Jiang P, Chan KC, Wong J, Cheng YKY, Liang RHS, et al. Plasma DNA Tissue Mapping by Genome-wide Methylation Sequencing for Noninvasive Prenatal, Cancer, and Transplantation Assessments. *Proc Natl Acad Sci U S A* (2015) 112(40):E5503–12. doi:10.1073/pnas.1508736112

Copyright © 2026 Gupta, Wojciechowski, Sener, Gong, Dunn, Costa, Odorico, Daloul, Rohan, Biagini, Barnes, Kaur, Gude, Ahmed, Xie, Spellicy, Al Haj Baddar, Bloom, Demko, Prewett, Gauthier, Borade, Tabriziani and Akkina. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

## GLOSSARY

<b>ABMR</b> antibody-mediated rejection	<b>KALT</b> kidney-after-liver transplant
<b>ALT</b> alanine aminotransferase	<b>KDPI</b> Kidney Donor Profile Index
<b>ALP</b> alkaline phosphatase	<b>KT</b> kidney transplant
<b>AMBR</b> antibody-mediated rejection	<b>LAKT</b> liver-after-kidney transplant
<b>AR</b> acute rejection	<b>LK</b> liver–kidney
<b>AST</b> aspartate aminotransferase	<b>LKT</b> liver–kidney transplant
<b>BMI</b> body mass index	<b>LT</b> liver transplant
<b>BNP</b> B-type natriuretic peptide	<b>MOT</b> multi-organ transplantation
<b>BPAR</b> biopsy-proven acute rejection	<b>MOTR</b> Multi-Organ Transplant Recipients study
<b>cfDNA</b> cell-free DNA	<b>NIPT</b> noninvasive prenatal testing
<b>CNI</b> calcineurin inhibitor	<b>NT-proBNP</b> N-terminal pro-B-type natriuretic peptide
<b>cp/mL</b> copies per milliliter	<b>OPTN</b> Organ Procurement and Transplantation Network
<b>dd-cfDNA</b> donor-derived cell-free DNA	<b>PAK</b> pancreas-after-kidney transplant
<b>DQS</b> donor quantity score	<b>PAKT</b> pancreas-after-kidney transplant
<b>DSA</b> donor-specific antibodies	<b>PKT</b> pancreas–kidney transplant
<b>eGFR</b> estimated glomerular filtration rate	<b>sCr</b> serum creatinine
<b>HK</b> heart–kidney	<b>SHKT</b> simultaneous heart–kidney transplant
<b>HKT</b> heart–kidney transplant	<b>SPKT</b> simultaneous pancreas–kidney transplant
<b>HT</b> heart transplant	<b>SLKT</b> simultaneous liver–kidney transplant
<b>IQR</b> interquartile range	<b>SNP</b> single-nucleotide polymorphism
<b>KAHT</b> kidney-after-heart transplant	<b>SRTR</b> Scientific Registry of Transplant Recipients
	<b>TCMR</b> T-cell–mediated rejection